| 1 - Cover | 1 |
| 2 - Agenda | 5 |
| 3 - Welcome and Introductions | 7 |
| 4 - AOAC Policies and Procedures | 18 |
| 5 - SPDS Project Overview | 53 |
| 6 - Working Group Standard Method Performance Requirements | 77 |
| 6A - Anthocyanins Presentation | 79 |
| 6B - Anthocyanins SMPR | 87 |
| 6C - Chondroitin Presentation | 93 |
| 6D - Chondroitin SMPR (Screening) | 111 |
| 6E - Chondroitin SMPR (Quantitative) | 119 |
| 6F - PDE5 Inhibitors Presentation | 125 |
| 6G - PDE5 Inhibitors SMPR (Screening) | 145 |
| 6H- PDE5 Inhibitors SMPR (Identification) | 155 |
| 6I - PDE5 Inhibitors SMPR (Quantitative) | 165 |
| 6J - Supplemental List of PDE5 Inhibitors | 173 |
| 7 - Launch of New Working Groups | 205 |
| 7A - Ashwagandha Presentation | 207 |
| 7B - Cinnamon Presentation | 235 |
| 7C - Folin C Presentation | 251 |
| 8 - SPDS Advisory Panel Update | 261 |
| 9 - Next Steps | 263 |
| Annex I - SPDS Resources | 267 |
| Annex II - Why Participate? | 269 |
| Annex III - WG Agenda | 275 |